These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36477995)

  • 1. Factors affecting time to treatment initiation after diagnosis for multidrug-resistant/rifampicin-resistant tuberculosis patients: A mixed-methods study in Jakarta, Indonesia.
    Silitonga P; Jiang W; Wyatt S; Burhan E; Kes EFM; Long Q
    Trop Med Int Health; 2023 Jan; 28(1):43-52. PubMed ID: 36477995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.
    Bykov I; Dyachenko O; Ratmanov P; Liu H; Liang L; Wu Q
    BMC Infect Dis; 2022 Jul; 22(1):612. PubMed ID: 35831812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GeneXpert
    Christopher PM; ; Widysanto A
    Int J Mycobacteriol; 2019; 8(4):351-358. PubMed ID: 31793505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis Pathways to Care and Transmission of Multidrug Resistance in India.
    Atre SR; Jagtap JD; Faqih MI; Dumbare YK; Sawant TU; Ambike SL; Bhawalkar JS; Bharaswadkar SK; Jogewar PK; Adkekar RS; Hodgar BP; Jadhav V; Mokashi ND; Golub JE; Dixit A; Farhat MR
    Am J Respir Crit Care Med; 2022 Jan; 205(2):233-241. PubMed ID: 34706203
    [No Abstract]   [Full Text] [Related]  

  • 7. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study.
    van Kampen SC; Susanto NH; Simon S; Astiti SD; Chandra R; Burhan E; Farid MN; Chittenden K; Mustikawati DE; Alisjahbana B
    PLoS One; 2015; 10(6):e0123536. PubMed ID: 26075722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
    Ngabonziza JS; Habimana YM; Decroo T; Migambi P; Dushime A; Mazarati JB; Rigouts L; Affolabi D; Ivan E; Meehan CJ; Van Deun A; Fissette K; Habiyambere I; Nyaruhirira AU; Turate I; Semahore JM; Ndjeka N; Muvunyi CM; Condo JU; Gasana M; Hasker E; Torrea G; de Jong BC
    Int J Tuberc Lung Dis; 2020 Mar; 24(3):329-339. PubMed ID: 32228764
    [No Abstract]   [Full Text] [Related]  

  • 11. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment attrition and treatment initiation delay among rifampicin-resistant tuberculosis patients in Lagos, Nigeria: a retrospective cohort study.
    Adejumo OA; Daniel O; Adepoju VA; Onoh MO; Sokoya OD; Abdur-Razzaq H; Moronfolu O; Oyadotun OM; Olusola-Faleye B
    Trans R Soc Trop Med Hyg; 2022 Dec; 116(12):1154-1161. PubMed ID: 35710310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation.
    Jeon D; Kang H; Kwon YS; Yim JJ; Shim TS
    J Korean Med Sci; 2020 Sep; 35(35):e284. PubMed ID: 32893517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: A retrospective study.
    Htun YM; Khaing TMM; Aung NM; Yin Y; Myint Z; Aung ST; Soonthornworasiri N; Silachamroon U; Kasetjaroen Y; Kaewkungwal J
    PLoS One; 2018; 13(12):e0209932. PubMed ID: 30596734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis.
    Tabriz NS; Skak K; Kassayeva LT; Omarkulov BK; Grigolashvili MA
    Microb Drug Resist; 2020 Aug; 26(8):997-1004. PubMed ID: 32181685
    [No Abstract]   [Full Text] [Related]  

  • 20. Microbiome in sputum as a potential biomarker of chronicity in pulmonary resistant to rifampicin-tuberculosis and multidrug-resistant-tuberculosis patients.
    Wiqoyah N; Mertaniasih NM; Artama WT; Matsumoto S
    Int J Mycobacteriol; 2021; 10(3):260-267. PubMed ID: 34494564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.